Sigyn Therapeutics, trading under the symbol SIGY on the OTC Markets, is a clinical-stage biopharmaceutical company dedicated to the development of novel protein-based therapies for cardiovascular and autoimmune diseases. Founded in 2019 as a spin-out from academic research laboratories, the company leverages proprietary protein engineering and high-throughput screening platforms to design biologics that address underlying disease mechanisms. Sigyn’s leadership team, led by CEO Dr. Alexandra Rivera, combines expertise in molecular biology, translational medicine and regulatory strategy to advance its pipeline through preclinical and early clinical stages.
At the core of Sigyn’s research are two lead programs: a recombinant collagen mimetic designed to promote vascular repair in patients with aortic aneurysms, and an engineered immunoregulatory protein aimed at modulating T-cell activity in autoimmune conditions such as rheumatoid arthritis. Both candidates have demonstrated favorable safety profiles in animal models and are currently positioned for first-in-human studies. The company’s R&D operations include in-house analytical development, cell culture manufacturing capabilities and partnerships with contract research organizations for toxicology and pharmacokinetic assessments.
In addition to its proprietary pipeline, Sigyn has established strategic collaborations with academic centers in North America and Europe to explore broader applications of its protein platform in fibrotic and inflammatory disorders. The company’s manufacturing strategy emphasizes scalable cGMP production to support both clinical trials and potential commercial supply. Headquartered in Cambridge, Massachusetts, Sigyn maintains research hubs in San Diego and Munich to facilitate access to key scientific talent and global regulatory expertise.
Under the guidance of its board of directors, which includes industry veterans in biomanufacturing and clinical development, Sigyn Therapeutics continues to build its intellectual property portfolio while preparing for pivotal regulatory interactions. The company’s long-term vision is to introduce first-in-class biologics that not only treat symptoms but also promote tissue repair and immune homeostasis, addressing significant unmet needs in cardiovascular and autoimmune patient populations.
AI Generated. May Contain Errors.
